Amicus shares surge on preclinical Pompe disease results; Isis earns $5M payment from Biogen Idec;

@FierceBiotech: $MRK and $NVO join an open-source R&D club with $AMGN, $SNY and Ono. Report | Follow @FierceBiotech

@JohnCFierce: Game-changer: A new plan takes shape to spur the U.K.'s biotech cluster. More | Follow @JohnCFierce

@DamianFierce: Schleifer on PCSK9 launches: Initial splash w/ severe patients and "early adopters" followed by a 2nd boom when outcomes data come out $REGN. | Follow @DamianFierce

> Shares of Amicus Therapeutics surged this morning after the biotech released some preclinical results on its therapy for Pompe disease. Release

> Isis ($ISIS) earned a $5 million milestone from Biogen Idec ($BIIB) in exchange for progress on an unidentified neurological disorder. Release

Medical Device News

@FierceMedDev: Biosensors Japan's PhIII trial of drug eluting has enrolled patients. More | Follow @FierceMedDev

@VarunSaxena2: Check out these next-gen devices in the incubator pipeline: (Lots of pictures of new devices.) Report | Follow @VarunSaxena2

@EmilyWFierce: Pioneer in BRCA1 research once received a cease-and-desist letter from $MYGN's legal department. NYT story | Follow @EmilyWFierce

> Ahead of BD deal close, CareFusion partners to sell ventilators, sleep apnea device. Story

> Days after permanent injunction, Maquet is whacked with another FDA recall. Article

Pharma News

@FiercePharma: ICYMI yesterday: Serum Institute and Cipla in early merger talks. Story from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Daiichi's new clot-fighter Savaysa can't make up for $2.6B Benicar patent loss: analysts. Article | Follow @CarlyHFierce

> FDA puts off Mylan's Nexium generic, giving Teva's version free rein. More

> Showdown time for Amgen, Sandoz, with Neupogen biosim hearing set March 2. Article

Pharma Manufacturing News

> Cambrex ponies up $50M for another expansion of its Iowa API plant. News

> New Jersey company invests $1M in plant, now offers contract manufacturing. Article

> FDA letter takes issue with Micro Labs' data practices. Report

> China FDA orders respiratory API recalled after 'fur' like impurities found. Story

> Cipla to build a manufacturing plant in Morocco with local partners. Article

Biotech Research News

> UC Davis team finds a prime drug candidate for neuropathic pain. More

> Neuroscience project tries to put the immune system to work against Alzheimer's. Report

> Psychedelic drug shows promise as a new treatment for allergic asthma. Article

> Peptide could play a role in preventing binge eating, obesity. Item

> Antibody developed by NTU-led team in Singapore tracks flu recovery. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.